CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak : ACAM2000 vaccine
-
August 9, 2022
Details:
-
Corporate Authors:
-
Description:ACAM2000 is licensed by the U.S. Food and Drug Administration for immunization against smallpox disease for people determined to be at high risk for smallpox infection. It has been made available for the prevention of monkeypox disease under an Expanded Access Investigational New Drug application (EA-IND).
CDC recommends that vaccination with ACAM2000 can be considered for people aged 1 year and older who have been determined to be at high risk for infection to prevent monkeypox disease.
Vaccination Schedule : ACAM2000 vaccine is licensed as a single dose.
Adverse events following ACAM2000, including myopericarditis/pericarditis or vaccinia virus transmission to household contacts, can be serious. ACAM2000 will be made available for individuals who decide in consultation with their healthcare provider that the potential benefits of vaccination outweigh potential risks from ACAM2000 adverse events.
-
Content Notes:Interim guidance -- Vaccination Schedule -- Table 4. Vaccination Schedule -- Duration of Immunity -- Evidence Quality -- Administration -- Coadministration -- Patient counseling -- Safety -- Table 5. Contraindications -- Resources.
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: